Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?
Portfolio Pulse from Vandana Singh
Akero Therapeutics Inc (NASDAQ:AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). The drug was not statistically significant in improving liver scarring without worsening of NASH, causing shares to tumble. However, statistically significant rates of NASH resolution and improvements in non-invasive liver injury and fibrosis markers were observed in EFX-treated groups.
October 10, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akero Therapeutics' stock price fell due to the lack of significant improvement in liver scarring in their Phase 2b study of efruxifermin. However, the drug showed significant rates of NASH resolution and improvements in non-invasive liver injury and fibrosis markers.
The stock price of Akero Therapeutics fell due to the disappointing results of their Phase 2b study of efruxifermin. The drug did not show a significant improvement in liver scarring, which was a key endpoint of the study. However, the drug did show significant rates of NASH resolution and improvements in non-invasive liver injury and fibrosis markers, which could potentially offset some of the negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100